July 27, 2015
High Potency Product Manufacturing
Key selection criteria when evaluating an outsourcing partner
Approximately 25% of drugs in development worldwide are classified as highly potent, with this percenta…
July 27, 2015 Four decades delivering contract pharma solutions for our partners
Alkermes Contract Pharma Services provides solid dosage form product development, scale-up and manufacturing services along with sterile fill-finish capabilities to the global phar…
July 27, 2015 Alkermes’ successful approach to commercialscal final dosage manufacture of drug product containing highly potent API
• Donor site capacity issue where the company was seeking an outsourcing manufacturing partner for co…
July 27, 2015 Key success factors in fostering and maintaining a long-term strategic partnership
2012 will be regarded by many commentators as one of the most challenging years in the pharmaceutical industry’s history, due in no small part t…
June 5, 2015 This is a global, strategic sourcing position responsible for developing and executing sourcing strategies for multiple categories of spend that deliver value to the business by reducing risk, improving quality, and reducing costs.
• This inc…
Walt Berghahn , Healthcare Compliance Packaging Council (HCPC) || June 2, 2015 Spurred by several trends including the patent cliff, new product launches and changes in healthcare, the contract packaging market is looking at sustained growth in the years ahead
Patricia Hurley, Joan Boren and Costantino Congiatu, PPD || June 2, 2015 More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.
Kristin Brooks, Contract Pharma || May 19, 2015 Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain
Tim Wright, Editor || May 6, 2015 Herein are the results of our 2015 Annual Outsourcing Survey, where we call on you, the readers, to help us benchmark the state of the pharmaceutical outsourcing industry.
Eric S. Langer and Ronald A. Rader, BioPlan Associates || April 1, 2015 Now that the FDA has just approved its first product under biosimilar regulations—Zarxio—containing filgrastim (G-CSF), a biosimilar version of Neupogen from Amgen, we can expect some more rapid shifts in the market. Factors like how this…